Table 3.

Relation between the positivity of celiac disease specific antibodies and clinical presentation of ulcerative colitis

	tTG			DGP
Number of patients	Positive (n = 10)	Negative (n = 100)	p value*	Positive (n = 11)	Negative (n = 99)	p value*
Median age, year (range)	47.5 (19–82)	47.8 (25–68)	0.958	42.0 (19–82)	48.1 (24–68)	0.950
Mean disease duration (year)	12.8	9.3	0.462	11.0	9.6	0.586
Localization of the disease (n)			0.798			0.887
Pancolitis	5	50	0.533	6	50	0.526
Left-sided colitis	3	37	0.420	3	34	0.458
Proctitis	2	13	0.408	2	15	0.534
Medication (n)			0.084			0.279
Immunomodulators**	5	27	0.089	5	29	0.221
Corticosteroid	5	35	0.271	5	38	0.441
Mayo score	6.40 ± 1.80	2.60 ± 1.70	<0.01	6.10 ± 1.9	2.58 ± 1.94	<0.01
Laboratory values
Albumin (g/dl)	4.15 ± 0.36	4.21 ± 0.48	0.987	4.15 ± 0.08	4.14 ± 0.60	0.950
Total cholesterol (mg/dl)	173.1 ± 24.5	180.0 ± 30.7	0.358	163.4 ± 20.3	179.7 ± 31.1	0.03
Hemoglobin (g/dl)	12.6 ± 1.52	13.8 ± 2.30	0.107	13.1 ± 1.63	13.5 ± 1.75	0.953
CRP (mg/dl)	0.30 ± 0.31	0.19 ± 1.49	0.131	0.27 ± 0.25	0.20 ± 1.51	0.145

tTG serum tissue trans glutaminase (IgA), DGP serum deamidated gliadin peptide (IgA), CRP C-reactive protein

* Statistical comparison between sero-positive and sero-negative

** Azathioprine, 6-mercaptopurine, calcineurin inhibitor (tacrolimus) and anti-TNF agents